Personalis (NASDAQ:PSNL) Shares Gap Up – What’s Next?

Personalis, Inc. (NASDAQ:PSNL)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $6.04, but opened at $6.82. Personalis shares last traded at $6.6670, with a volume of 1,246,028 shares.

Wall Street Analyst Weigh In

PSNL has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Needham & Company LLC raised their target price on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Guggenheim raised their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Morgan Stanley reduced their target price on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday. Finally, Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $11.00.

Personalis Stock Up 5.0%

The company’s 50-day moving average price is $6.66 and its 200-day moving average price is $8.11. The firm has a market cap of $702.67 million, a price-to-earnings ratio of -6.58 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The company had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. Analysts predict that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Institutional Trading of Personalis

Institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd grew its position in shares of Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Personalis in the fourth quarter valued at about $31,000. Legal & General Group Plc acquired a new stake in shares of Personalis in the second quarter valued at about $30,000. BNP Paribas Financial Markets grew its position in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares during the period. Finally, AQR Capital Management LLC acquired a new stake in shares of Personalis in the fourth quarter valued at about $82,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.